@article{32d75b57f24446cd97fa75f85e7ffbb2,
title = "Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies",
author = "Bruno Bastos",
note = "Carneiro, B. A., Cavalcante, L., Mahalingam, D., Saeed, A., Safran, H., Ma, W. W., Coveler, A. L., Powell, S., Bastos, B., Davis, E., Sahai, V., Mikrut, W., Longstreth, J., Smith, S., Weisskittel, T., Li, H., Borden, B. A., Harvey, R. D., Sahebjam, S., Cervantes, A., … Munster, P. (2024). Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(3), 522{\textendash}531. https://doi.org/10.1158/1078-0432.CCR-23-1916",
year = "2024",
month = feb,
day = "1",
language = "American English",
volume = "30",
journal = "Clinical Cancer Research",
}